Boniva Injection (Ibandronate Sodium Injection) Drug Information: Overdosage and Contraindications

May 25, 2012

Osteoporosis is a condition of increased susceptibility to fracture due to fragile bone.
Osteoporosis weakens bone and increases risk of bone fracture.
Bone mass (bone density) decreases after 35 years of age and decreases more rapidly in women after menopause.
Key risk factors for osteoporosis include genetics, lack of exercise, lack of calcium and vitamin D, personal history of fracture as an adult, cigarette smoking, excessive alcohol consumption, history of rheumatoid arthritis, low body weight, and family history of osteoporosis.
Patients with osteoporosis have no symptoms until bone fractures occur.
The diagnosis of osteoporosis can be suggested by X-rays and confirmed by tests to measure bone density.
Treatments for osteoporosis, in addition to prescription osteoporosis medications, include stopping use of alcohol and cigarettes, and assur...

Boniva Injection

font size

No cases of overdose were reported in premarketing studies with BONIVA Injection (ibandronate sodium injection) . Intravenous overdosage may result in hypocalcemia, hypophosphatemia, and hypomagnesemia. Clinically relevant reductions in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate, respectively.

Dialysis would not be beneficial unless it is administered within 2 hours following the overdose.

Known hypersensitivity to BONIVA Injection (ibandronate sodium injection) or to any of its excipients
Uncorrected hypocalcemia (see PRECAUTIONS: General)

Last reviewed on RxList: 2/11/2009
This monograph has been modified to include the generic and brand name in many instances.